Snapshot · Russell 3000 · generated 2026-09-19 21:53 UTC
GYRE — Gyre Therapeutics, Inc.
EXPENSIVE (MOS -6191.7%) · Quality 49/100
Price
7.55
Intrinsic value
0.12
Margin of safety
-6191.7%
Implied growth (reverse DCF)
+60.0%
model assumes +0.0%
Value Score
-5.3
Quality
49
Psychology
-44.4
Discovery
133
price/volume attention only
Moat score
46.8
erosion: none
Value Score: bottom 2% of Russell 3000 · Quality: bottom 36%
Open the interactive Deep Dive for GYRE →
Use this data programmatically
This page's numbers are also available as JSON at /api/v1/deep-dive/GYRE - see the API docs for the full read-only surface, including an MCP server for AI assistants.
Common questions
Is GYRE undervalued?
As of 2026-09-19, GYRE trades at 7.55 against a computed intrinsic value of 0.12 (-6191.7% margin of safety) - StocksDeepDive's valuation label for this is EXPENSIVE. This is a described calculation from public data, not a recommendation.
What is Gyre Therapeutics, Inc.'s Value Score?
Gyre Therapeutics, Inc.'s Value Score is -5.3 as of 2026-09-19 - it combines value, quality, crowd psychology and market attention into one number.